Stockscreener 앱 받기
248.08
0.73%
-1.83
시간 외 거래:
248.40
0.32
+0.13%
전일 마감가:
$249.91
열려 있는:
$251.005
하루 거래량:
5.42M
Relative Volume:
0.78
시가총액:
$438.31B
수익:
$62.82B
순이익/손실:
$3.60B
주가수익비율:
122.36
EPS:
2.0274
순현금흐름:
$19.98B
1주 성능:
-4.98%
1개월 성능:
+10.28%
6개월 성능:
+12.72%
1년 성능:
+27.22%
1일 변동 폭
$245.05
$251.66
1주일 범위
$245.05
$260.92
52주 변동 폭
$184.63
$261.63
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
248.08 | 441.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,188.58 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 623.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
123.54 | 308.90B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 295.03B | 54.66B | 13.58B | 16.05B | 7.0171 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-30 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100 - GuruFocus
West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business - Yahoo Finance UK
ABBV Maintained by B of A Securities -- Price Target Raised to $276 - GuruFocus
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner - AOL.com
AbbVie Inc. Stock 12‑Month Price Target Raised to $263.72, Implies 6% Upside - TradingView
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands - Investorideas.com
ABBV Maintains Overweight Rating -- Price Target Raised to $295 - GuruFocus
BofA Securities Adjusts AbbVie Price Target to $276 From $234 - marketscreener.com
ABBV Maintained by RBC Capital -- Price Target Raises to $260 - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $276 to $295 - Moomoo
AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says - marketscreener.com
Dividend Roundup: Costco, Phillips 66, Abbott Labs, AbbVie, and more (DVY:NASDAQ) - Seeking Alpha
RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating - marketscreener.com
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (NYSE:ABBV): Dividend Stability Under The Spotlight - Kalkine Media
JPMorgan Adjusts Price Target on AbbVie to $280 From $260 - marketscreener.com
ABBV Maintains Buy Rating -- Price Target Raised to $261 - GuruFocus
ABBV Maintained by JP Morgan -- Price Target Raised to $280 - GuruFocus
ABBV Leads Its Peer Group. You Pay For That - Trefis
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth - TradingView
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? - The Motley Fool
AbbVie stock trades steadily as investors weigh immunology and oncology pipeline - AD HOC NEWS
Guggenheim raises Abbvie stock price target to $261 on Rinvoq strength - Investing.com Canada
Guggenheim Adjusts Price Target on AbbVie to $261 From $249 - marketscreener.com
AbbVie Stock Traded Its Old Story for New Growth. Here Is The Price. - Trefis
AbbVie (NYSE:ABBV) Dividend Streak Gains Fresh Market Focus - Kalkine Media
AbbVie accused of hiding painful lump risk from Juvederm patients in new lawsuit - Claim Depot
ABBV Stock Quote Price and Forecast - CNN
AbbVie Stock Traded Its Old Story For New Growth. Here Is The Price. - Trefis
AbbVie Earnings Preview: What to Expect - Barchart.com
AbbVie Inc. outlines long-term growth drivers as a major biopharma player - AD HOC NEWS
More Than 2.5 Million Generic Prednisolone Acetate Eye Drops Recalled - Optometry Advisor
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years - Barchart.com
AbbVie (NYSE:ABBV) Turns Rotation Into A Growth Story - Kalkine Media
AbbVie (ABBV) Expands Tepkinly Label for Follicular Lymphoma Tre - GuruFocus
AbbVie, Genmab granted EU label expansion for Tepkinly in follicular lymphoma - Seeking Alpha
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List) - Yahoo Finance
Global markets live: Broadcom, Meta, Walmart, Intel, AbbVie… - marketscreener.com
Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280 - Moomoo
EC approves AbbVie’s Tepkinly combination for follicular lymphoma - Pharmaceutical Business review -
AbbVie Inc. outlines long-term growth strategy as a major biopharma player - AD HOC NEWS
AbbVie (ABBV) Lowers Q2 Earnings Guidance Amid IPR&D Expenses - GuruFocus
AbbVie (ABBV) Anticipates Earnings Impact from IPR&D Expenses - GuruFocus
AbbVie revises guidance; expects Q2 EPS to include unfavorable impact of $0.17 - MSN
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie (ABBV) Receives EU Approval for TEPKINLY in Follicular Ly - GuruFocus
AbbVie Announces TEPKINLY® in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Investing News Network
Abbvie Says Tepkinly In Combination With Lenalidomide And Rituximab Approved By European Commission - TradingView
AbbVie's Post-Humira Triumph: Skyrizi and Rinvoq Drive Sector-Leading Growth - Kavout | AI
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.22%
1.23%
자본화:
|
볼륨(24시간):